DOCSLIB.ORG

Quantitation of the Number of Molecules of Glycophorins C and D on Normal Red Blood Cells Using Radioiodinatedfab Fragments of Monoclonal Antibodies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quantitation of the Number of Molecules of Glycophorins C and D on Normal Red Blood Cells Using Radioiodinatedfab Fragments of Monoclonal Antibodies Quantitation of the Number of Molecules of Glycophorins C and D on Normal Red Blood Cells Using RadioiodinatedFab Fragments of Monoclonal Antibodies By Jon Smythe, Brigitte Gardner, andDavid J. Anstee Two rat monoclonal antibodies (BRAC 1 and BRAC 1 1 ) cytes. Fabfragments of BRAC 1 1 and ERIC 10 gave values have been produced. BRAC 1 recognizes an epitope com- of 143,000 molecules GPC per red blood cell (RBC). Fab mon to the human erythrocyte membrane glycoproteins fragments of BRAC1 gave 225,000 molecules of GPC and glycophorin C (GPC) and glycophorin D (GPD). BRAC 11 GPD per RBC. These results indicate that GPC and GPD is specific for GPC. Fabfragments of these antibodies and together are sufficiently abundantto provide membrane at- BRlC 10, a murine monoclonal anti-GPC,were radioiodin- tachment sites for all ofthe protein 4.1 in normal RBCs. ated and used in quantitative binding assays to measure 0 1994 by The American Societyof Hematology. the number of GPC and GPD molecules on normal erythro- HE SHAPE AND deformability of the mature human (200,000)" and those reported for GPC (50,000).7 This nu- Downloaded from http://ashpublications.org/blood/article-pdf/83/6/1668/612763/1668.pdf by guest on 24 September 2021 T erythrocyte is controlled by a flexible two-dimensional merical differencehas led to the suggestion that a significant lattice of proteins, which together comprise the membrane proportion of protein 4.1 in normal erythrocyte membranes skeleton.' The major components of the skeleton are spec- must be bound to sites other than GPC and GPD.3 The trin, actin, ankyrin, and protein 4.1. The skeleton is at- value of 50,000 molecules of GPC per RBC was obtained tached to the cytoplasmic face of the lipid bilayer through using radioiodinated murine monoclonal IgG anti-GPC.7 interactions involving ankyrin and protein 4. l. It is known This value is a minimum estimate, since accessibilityto the that ankyrin interacts with the N-terminal cytoplasmic do- relevant epitope on all GPC molecules may beimpeded by main of the integral membrane protein, band 3. The way in steric hindrance resulting from the size of whole IgG mole- which protein 4.1 binds to the plasma membrane is less cules. In this report, we have measured the abundance of clearly understood. Evidence has been presentedto support GPC using Fab fragments of rat and murine monoclonal interaction of protein 4.1 with band 3,2-4glycophorin A,' anti-GPC antibodies. We also describe the use of Fab frag- glycophorin C (GPC) and glycophorin D (GPD),6s7 and ments from a rat monoclonal antibody that recognizes an phospholipid.' The relative importance ofthese interactions epitope common to GPC and GPD. remains unclear. However, there is strong evidence in sup- MATERIALSAND METHODS port of a role for GPC and GPD in vivo. GPC andGPD are Human RBCs were obtained from Blood Services South West, present in skeletons preparedfrom normal erythrocytes,but Bristol, UK. Rat monoclonal antibodies (BRACs 1 and 11) were are absent from skeletons prepared from the erythrocytes produced in LOU rats in response to two intraperitoneal injections of individuals with hereditary elliptocytosis resulting from of human RBCs (0.2 ml of 50% suspension in phosphate-buffered homozygous protein 4. l defi~iency.~,~Erythrocyte mem- saline [PBS], pH 7) 24 days apart. Three days after the second im- branes of the Leach phenotype, which have a total defi- munization, splenocytes were fused with Y3.Ag. 1.2.3. myeloma ciency of GPC and GPD,7lack a membrane binding site for cells," in the ratio 4: I, using PEG 3500. Hybrid cells were selected protein 4.1, since incontrast to normal membranes, protein by culture in Dulbecco's modified Eagle's medium (DMEM; con- 4.1 is readily extracted from Leach phenotype membranes taininghypoxanthine, thymidine, aminopterin [HAT]) supple- mented with 20% fetal bovine serum (F'BS) and 10% Y3 culture under the low ionic strength conditions used to isolate spec- supernatant in the presence of irradiated 3T3 fibroblasts. BRICs 4 trin." and 10, murine monoclonal antibodies to GPC, were as previously One problem concerning interpretation of the in vivo sig- described.' Pronase, trypsin, and chymotrypsin treatment of RBCs nificance of GPC and GPD as membrane binding sites for were as described el~ewhere,'~ was as the treatment of RBCs with protein 4.1 has been the apparent difference between the sialidasei4and with 2 aminoethylisothiouronium bromide (AET).'' number of protein 4.1 molecules per red blood cell (RBC) Immunoblotting was performed as described el~ewhere,'~except that 5% wt/vol bovine milk powder was used as the blocking agent, Immobilon-P membranes (Millipore Ltd,Watford, UK) were used, From the International Blood Group Reference Laboratory, Bris- and rabbit anti-rat peroxidase conjugate (DAKO, High Wycombe, tol, UK; and the Department of Haematology, St Mary's Hospital UK) was used with the BRAC antibodies. The rat monoclonal anti- Medical School, London, UK. body isotypes were determined using a dot-blot method essentially Submitted May 25, 1993; accepted November 5, 1993. as described by McDougal et IgG was purified from cell-culture Presented in part at the Annual Meeting of the British Blood supernatant using Protein A Sepharose (Pharmacia, Milton Transfusion Society, York, UK, September 8-11, 1992 and pub- Keynes, UK) andIgM was purified using ion exchange on Q Seph- lished in Transf Med 2.69, 1992 (suppl l). arose fast-flow followed by gel filtration through Sephacryl S300 Address reprint requests to David J. Anstee, PhD, Director, ln- (Pharmacia) as recommended by the manufacturer. Methods for ternational Blood Group Reference Laboratory, Southmead Rd, the purification of Fab fragments, radiolabeling of whole immuno- Bristol BSI0 5ND,UK. globulin and Fab fragments, and their use in quantitative binding, The publication costs of this article were defrayed in part by page functional affinity, and competitive inhibition assays were as pre- charge payment. This article must therefore be hereby marked viously described." "advertisement" in accordance with 18 U.S.C.section I734 solely to RESULTS indicate this fact. 0 1994 by TheAmerican Society of Hematology. Characterization of rat monoclonal antibodies BRAC 1 0004-4971/94/8306-0002~3.00/0 and BRAC 11. BRAC 1 and BRAC l1 agglutinated nor- 1668 Blood, Vol83, No 6 (March 15). 1994: pp 1668-1 672 WANTITATION OF GLYCOPHORINS C AND D ONRBCs Origin - MW 40K - MW 32K - Downloaded from http://ashpublications.org/blood/article-pdf/83/6/1668/612763/1668.pdf by guest on 24 September 2021 MW 30K Fig 1. lmmunoblotting with BRAC 1 and BRAC - 11. Erythrocyte membrane components were sep- arated under nonreducing conditions by sodium do- decyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10% (wt/vol) acrylamide gels with a 3% (wt/vol) overlay." Lanes a and 1, normal erythrocyte membranes.Lanes b and g, mem- branes from Leach phenotype erythrocytes. Lanes ! c and h, membranes from trypsin-treated normal erythrocytes. Lane d. membranes from Gerbich- negative erythrocytes of the Yus type. Lane e, a bcde fgh membranes from Gerbich-negative erythrocytes of the Ge phenotype. BRAC 1 BRAC 11 mal RBCs, but failed to react with RBCs ofthe Leach phe- ration (Scatchard analysis; Fig 2 and Table l). Values ob notype, which lack GPC and GPD. The reactivity of both tained with BRAC 1 gave site numbers for GPC plus GPD antibodies was unaffected by prior treatment of normal averaging 7,000 per RBC using IgMand 238,000 (corrected RBCs with chymotrypsin, sialidase, or AET. BRAC 1 re- to 225,000 assuming binding to Leach phenotype RBCs acted with pronase-treated RBCs and gave markedly re- [Table l] represents nonspecific binding) using Fab frag- duced reactions with trypsin-treated normal RBCs. BRAC 11 failed to react with either pronase-treated or trypsin- treated normal RBCs. Table 1. Number of Available Binding Sites on RBCs for Anti-GPC (BRAC 11, BRlC 4, BRlC 10) and Anti-GPC/D (BRAC 1) Analysis of BRAC 1 and BRAC I l by immunoblotting and Values of Affinity Constants showed that BRAC 1 bound to both GPC and GPD in nor- Sites per RBC mal RBC membranes, but failed to react with membranes Affinity of the Leach phenotype and gave very weak reactivity with Antibody Normal Leach K (x 10' mol/L") trypsin-treatednormal membranes (Fig la throughc). BRlC 4 IgG 62,525 ? 3,9613.000 (1) l .4 f 0.7 BRAC 1 also reacted with the abnormal GPC found in (16) (4) Gerbich-negative RBCs of the Yus type, but not with the BRlC 10 IgG 47,683 ? 4,4964.000 (2)4.9 f 1.8 abnormal GPC found in Gerbich-negativeRBCs of the Ge (4) (16) type (Fig Idand e). BRAC 1 l bound onlyto GPC in normal BRlC 10 Fab 142,463 f 13,660 ND 0.67 t 0.02 RBCs and failed to react with membranes ofthe Leach phe- (8) (7) notype or trypsin-treatednormal membranes (Fig If BRAC 1 1 IgG 29,456 f 1,065 ND 2.3 (2) through h). (5) Quantitative binding experiments using rat and murine BRAC11Fab 143,410t10.448 ND 0.12 (2) (4) IO monoclonalantibodies GPCand GPD. Rat monoclonal BRAC 1 IgM 7,374 ? 1,225 ND ND antibodies BRAC 1 and BRAC 1 1 and murine monoclonal (5) antibody BRIC 10 were purified and Fab fragments pre- BRAC 1 Fab 238,721 ? 22,38013,380 t 2.464 0.22 (2) pared from eachantibody. The purified antibodies and Fab (3) (4) fragments were radioiodinated and usedin quantitative Mean t SD values are givenfor three or more measurements (the num- binding assays.
Load more

Recommended publications
  • Duffy, and Mnss Group Systems
    Blood Groups – Duffy, and MNSs Group Systems Qun Lu, MD Assistant Professor Division of Transfusion Medicine Department of Pathology and Laboratory Medicine UCLA, School of Medicine Los Angeles, California 2009-03-12 Duffy Blood Group System History . 1950: Mrs. Duffy, a multiply transfused hemophiliac woman, developed an antibody not reacting with the known RBC antigens. Corresponding antigen was named after Mrs. Duffy . 1951: Fyb antibody was described in a woman with 3 pregnancies. 1955: Majority of blacks tested Fy(a-b-) . 1975: Fy(a-b-) RBCs were shown to resist infection by malaria organism Plasmodium vivax. Later: more Duffy antigens (Fy3, Fy4, Fy5, Fy6) were discovered . ISBT: 008 for the Duffy Blood Group Duffy Antigens . Most common: Fya and Fyb. Present at 6 weeks of gestation, well developed at birth – anti- Fy can cause hemolytic disease of newborn . Duffy antigens can be destroyed by enzymes such as ficin, papain, bromelain, chymotrypsin, ZZAP . When compared to Rh or Kell antigens, Duffy antigens are not very immunogenic. So, anti-Fya or anti-Fyb is not common. Fy (a-b-) is not Fy null, but homozygous for Fyb gene, they express Fyb antigen in other tissues, but not on RBCs → only will produce anti-Fya, not anti-Fyb. Fy (a-b-) is negative for Fy6 antigen which is the receptor for P. vivax (Fy6 is + when Fya + or Fyb+) Duffy Antigens . Phenotype Frequencies Chinese Phenotype Whites % Blacks % % Fy (a+b-) 17 9 90.8 Fy (a+b+) 49 1 8.9 Fy (a-b+) 34 22 0.3 Fy (a-b-) rare 68 0 White donor population: Fya: 66% Caucasians, 10% Blacks, 99% Asians Fya – units: 35% Fyb: 83% Caucasians, 23% Blacks, 18.5% Asians Fyb – units: 15% Fy3: 100% Caucasians, 32% Blacks, 99.9% Asians Duffy Antigens .
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Role of C5ar1 and C5L2 Receptors in Ischemia-Reperfusion Injury
    Journal of Clinical Medicine Article Role of C5aR1 and C5L2 Receptors in Ischemia-Reperfusion Injury Carlos Arias-Cabrales 1,* , Eva Rodriguez-Garcia 1, Javier Gimeno 2, David Benito 3, María José Pérez-Sáez 1, Dolores Redondo-Pachón 1, Anna Buxeda 1, Carla Burballa 1, Marta Crespo 1, Marta Riera 3,* and Julio Pascual 1,* 1 Department of Nephrology, Parc de Salut Mar, 08003 Barcelona, Spain; [email protected] (E.R.-G.); [email protected] (M.J.P.-S.); [email protected] (D.R.-P.); [email protected] (A.B.); [email protected] (C.B.); [email protected] (M.C.) 2 Department of Pathology, Parc de Salut Mar, 08003 Barcelona, Spain; [email protected] 3 Kidney Research Group, Hospital del Mar Medical Research Institute, IMIM, 08003 Barcelona, Spain; [email protected] * Correspondence: [email protected] (C.A.-C.); [email protected] (M.R.); [email protected] (J.P.) Abstract: The role of C5a receptors (C5aR1 and C5L2) in renal ischemia-reperfusion injury (IRI) is uncertain. We generated an in vitro model of hypoxia/reoxygenation with human proximal tubule epithelial cells to mimic some IRI events. C5aR1, membrane attack complex (MAC) and factor H (FH) deposits were evaluated with immunofluorescence. Quantitative polymerase chain reaction evaluated the expression of C5aR1, C5L2 genes as well as genes related to tubular injury, inflammation, and profibrotic pathways. Additionally, C5aR1 and C5L2 deposits were evaluated in kidney graft biopsies (KB) from transplant patients with delayed graft function (DGF, n = 12) and compared with Citation: Arias-Cabrales, C.; a control group (n = 8). We observed higher immunofluorescence expression of C5aR1, MAC and FH Rodriguez-Garcia, E.; Gimeno, J.; as higher expression of genes related to tubular injury, inflammatory and profibrotic pathways and Benito, D.; Pérez-Sáez, M.J.; of C5aR1 in the hypoxic cells; whereas, C5L2 gene expression was unaffected by the hypoxic stimulus.
    [Show full text]
  • The Membrane Complement Regulatory Protein CD59 and Its Association with Rheumatoid Arthritis and Systemic Lupus Erythematosus
    Current Medicine Research and Practice 9 (2019) 182e188 Contents lists available at ScienceDirect Current Medicine Research and Practice journal homepage: www.elsevier.com/locate/cmrp Review Article The membrane complement regulatory protein CD59 and its association with rheumatoid arthritis and systemic lupus erythematosus * Nibhriti Das a, Devyani Anand a, Bintili Biswas b, Deepa Kumari c, Monika Gandhi c, a Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India b Department of Zoology, Ramjas College, University of Delhi, India c University School of Biotechnology, Guru Gobind Singh Indraprastha University, India article info abstract Article history: The complement cascade consisting of about 50 soluble and cell surface proteins is activated in auto- Received 8 May 2019 immune inflammatory disorders. This contributes to the pathological manifestations in these diseases. In Accepted 30 July 2019 normal health, the soluble and membrane complement regulatory proteins protect the host against Available online 5 August 2019 complement-mediated self-tissue injury by controlling the extent of complement activation within the desired limits for the host's benefit. CD59 is a membrane complement regulatory protein that inhibits the Keywords: formation of the terminal complement complex or membrane attack complex (C5b6789n) which is CD59 generated on complement activation by any of the three pathways, namely, the classical, alternative, and RA SLE the mannose-binding lectin pathway. Animal experiments and human studies have suggested impor- Pathophysiology tance of membrane complement proteins including CD59 in the pathophysiology of rheumatoid arthritis Disease marker (RA) and systemic lupus erythematosus (SLE). Here is a brief review on CD59 and its distribution, structure, functions, and association with RA and SLE starting with a brief introduction on the com- plement system, its activation, the biological functions, and relations of membrane complement regu- latory proteins, especially CD59, with RA and SLE.
    [Show full text]
  • An Anticomplement Agent That Homes to the Damaged Brain and Promotes Recovery After Traumatic Brain Injury in Mice
    An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice Marieta M. Rusevaa,1,2, Valeria Ramagliab,1, B. Paul Morgana, and Claire L. Harrisa,3 aInstitute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom; and bDepartment of Genome Analysis, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands Edited by Douglas T. Fearon, Cornell University, Cambridge, United Kingdom, and approved September 29, 2015 (received for review July 15, 2015) Activation of complement is a key determinant of neuropathology to rapidly and specifically inhibit MAC at sites of complement and disability after traumatic brain injury (TBI), and inhibition is activation, and test its therapeutic potential in experimental TBI. neuroprotective. However, systemic complement is essential to The construct, termed CD59-2a-CRIg, comprises CD59a linked fight infections, a critical complication of TBI. We describe a to CRIg via the murine IgG2a hinge. CD59a prevents assembly targeted complement inhibitor, comprising complement receptor of MAC in cell membranes (16), whereas CRIg binds C3b/iC3b of the Ig superfamily (CRIg) fused with complement regulator CD59a, deposited at sites of complement activation (17). The IgG2a designed to inhibit membrane attack complex (MAC) assembly at hinge promotes dimerization to increase ligand avidity. CD59- sites of C3b/iC3b deposition. CRIg and CD59a were linked via the 2a-CRIg protected in the TBI model, demonstrating that site- IgG2a hinge, yielding CD59-2a-CRIg dimer with increased iC3b/C3b targeted anti-MAC therapeutics may be effective in prevention binding avidity and MAC inhibitory activity. CD59-2a-CRIg inhibited of secondary neuropathology and improve neurologic recovery MAC formation and prevented complement-mediated lysis in vitro.
    [Show full text]
  • The Gerbich Blood Group System: a Review
    Review The Gerbich blood group system: a review P.S. Walker and M.E. Reid Antigens in the Gerbich blood group system are expressed on glycoproteins are also known as CD236R, and they attach glycophorin C (GPC) and glycophorin D (GPD), which are both to the RBC membrane through an interaction with protein encoded by a single gene, GYPC. The GYPC gene is located on 4.1R and p55. GPC and GPD contain three domains: an ex- the long arm of chromosome 2, and Gerbich antigens are in- tracellular NH2 domain, a transmembrane domain, and an herited as autosomal dominant traits. There are 11 antigens in intracellular or cytoplasmic COOH domain (Figure 1). GPC the Gerbich blood group system, six of high prevalence (Ge2, Ge3, Ge4, GEPL [Ge10*], GEAT [Ge11*], GETI [Ge12*]) and and GPD are encoded by the same gene, GYPC. When the five of low prevalence (Wb [Ge5], Lsa [Ge6], Ana [Ge7], Dha fi rst AUG initiation codon is used, GPC is encoded, whereas [Ge8], GEIS [Ge9]). GPC and GPD interact with protein 4.1R, when the second AUG is used, GPD is encoded. Thus, GPD contributing stability to the RBC membrane. Reduced lev- is a shorter version of GPC, and the amino acids in GPD els of GPC and GPD are associated with hereditary elliptocy- are identical to those found in GPC but lacking the fi rst 21 tosis, and Gerbich antigens act as receptors for the malarial amino acids at the N-terminal of GPC.9,10 parasite Plasmodium falciparum. Anti-Ge2 and anti-Ge3 have caused hemolytic transfusion reactions, and anti-Ge3 has pro- duced hemolytic disease of the fetus and newborn (HDFN).
    [Show full text]
  • Flow Reagents Single Color Antibodies CD Chart
    CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n
    [Show full text]
  • Analysis of RNA Expression Profiles Identifies Dysregulated Vesicle Trafficking Pathways in Creutzfeldt-Jakob Disease
    Molecular Neurobiology (2019) 56:5009–5024 https://doi.org/10.1007/s12035-018-1421-1 Analysis of RNA Expression Profiles Identifies Dysregulated Vesicle Trafficking Pathways in Creutzfeldt-Jakob Disease Anna Bartoletti-Stella1 & Patrizia Corrado2 & Nicola Mometto2 & Simone Baiardi2 & Pascal F. Durrenberger3 & Thomas Arzberger4,5 & Richard Reynolds6 & Hans Kretzschmar5 & Sabina Capellari1,2 & Piero Parchi1,7 Received: 18 July 2018 /Accepted: 1 November 2018 /Published online: 16 November 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Functional genomics applied to the study of RNA expression profiles identified several abnormal molecular processes in experimental prion disease. However, only a few similar studies have been carried out to date in a naturally occurring human prion disease. To better characterize the transcriptional cascades associated with sporadic Creutzfeldt-Jakob disease (sCJD), the most common human prion disease, we investigated the global gene expression profile in samples from the frontal cortex of 10 patients with sCJD and 10 non-neurological controls by microarray analysis. The comparison identified 333 highly differentially expressed genes (hDEGs) in sCJD. Functional enrichment Gene Ontology analysis revealed that hDEGs were mainly associated with synaptic transmission, including GABA (q value = 0.049) and glutamate (q value = 0.005) signaling, and the immune/ inflammatory response. Furthermore, the analysis of cellular components performed on hDEGs showed a compromised regu- lation of vesicle-mediated transport with mainly up-regulated genes related to the endosome (q value = 0.01), lysosome (q value = 0.04), and extracellular exosome (q value < 0.01). A targeted analysis of the retromer core component VPS35 (vacuolar protein sorting-associated protein 35) showed a down-regulation of gene expression (p value= 0.006) and reduced brain protein levels (p value= 0.002).
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • CD59: a Long-Known Complement Inhibitor Has Advanced to a Blood Group System
    B LOOD G ROUP R EVIEW CD59: A long-known complement inhibitor has advanced to a blood group system C. Weinstock, M. Anliker, and I. von Zabern The blood group system number 35 is based on CD59, a 20-kDa by Zalman et al.1 from the group of H.J. Muller-Eberhard in La membrane glycoprotein present on a large number of different Jolla, California, and in 1988 by Schönermark et al. from the cells, including erythrocytes. The major function of CD59 is to group of G.M. Hänsch in Heidelberg (Germany).2 This inhibitor protect cells from complement attack. CD59 binds to complement components C8 and C9 and prevents the polymerization of C9, was published under the designations “HRF (homologous which is required for the formation of the membrane attack restriction factor)” and “C8bp (C8 binding protein),” complex (MAC). Other functions of CD59 in cellular immunity respectively, to describe its properties.1,2 “C8bp” indicates the are less well defined. CD59 is inserted into the membrane by a glycosylphosphatidylinositol (GPI) anchor. A defect of this anchor binding capacity for C8. The name “HRF” points to a species causes lack of this protein from the cell membrane, which leads to incompatibility of this “factor” that provides protection from an enhanced sensitivity towards complement attack. Patients with complement attack more effectively in a homologous (e.g., paroxysmal nocturnal hemoglobinuria (PNH) harbor a varying human erythrocytes as a target of human complement) than in percentage of red blood cell clones with a defect in GPI-anchored proteins, including CD59. The most characteristic symptoms of a heterologous system (e.g., human erythrocytes as a target of this disease are episodes of hemolysis and thromboses.
    [Show full text]
  • Anti-Glycophorin C Antibody (ARG41471)
    Product datasheet [email protected] ARG41471 Package: 100 μl anti-Glycophorin C antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes Glycophorin C Tested Reactivity Hu Tested Application FACS, ICC/IF, IHC-P, IP, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name Glycophorin C Antigen Species Human Immunogen Synthetic peptide of Human Glycophorin C. Conjugation Un-conjugated Alternate Names Glycophorin-D; CD236R; GPD; Glycophorin-C; Glycoprotein beta; Glycoconnectin; GPC; PAS-2; CD antigen CD236; GE; CD236; Sialoglycoprotein D; GYPD; PAS-2' Application Instructions Application table Application Dilution FACS 1:50 ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 IP 1:50 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control K562 Calculated Mw 14 kDa Observed Size ~ 39 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.4), 150 mM NaCl, 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide www.arigobio.com 1/2 Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol GYPC Gene Full Name glycophorin C (Gerbich blood group) Background Glycophorin C (GYPC) is an integral membrane glycoprotein.
    [Show full text]
  • Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells
    International Journal of Molecular Sciences Article Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells Sofía Valla 1,2 , Nourhan Hassan 3 , Daiana Luján Vitale 2,4 , Daniela Madanes 5, Fiorella Mercedes Spinelli 2,4, Felipe C. O. B. Teixeira 3, Burkhard Greve 6 , Nancy Adriana Espinoza-Sánchez 3,6 , Carolina Cristina 1,2, Laura Alaniz 2,4,* and Martin Götte 3,* 1 Laboratorio de Fisiopatología de la Hipófisis, Centro de Investigaciones Básicas y Aplicadas (CIBA), Universidad Nacional del Noroeste de la Provincia de Buenos Aires (UNNOBA), Libertad 555, Junín (B6000), Buenos Aires 2700, Argentina; sofi[email protected] (S.V.); [email protected] (C.C.) 2 Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires (CITNOBA, UNNOBA-UNSAdA-CONICET), Buenos Aires 2700, Argentina; [email protected] (D.L.V.); fi[email protected] (F.M.S.) 3 Department of Gynecology and Obstetrics, Münster University Hospital, Domagkstrasse 11, 48149 Münster, Germany; [email protected] (N.H.); [email protected] (F.C.O.B.T.); [email protected] (N.A.E.-S.) 4 Laboratorio de Microambiente Tumoral, Centro de Investigaciones Básicas y Aplicadas (CIBA), Universidad Nacional del Noroeste de la Provincia de Buenos Aires (UNNOBA), Libertad 555, Junín (B6000), Citation: Valla, S.; Hassan, N.; Vitale, Buenos Aires 2700, Argentina 5 Laboratorio de Inmunología de la Reproducción, Instituto de Biología y Medicina Experimental—Consejo D.L.; Madanes, D.; Spinelli, F.M.; Nacional de Investigaciones Científicas y Técnicas (IBYME-CONICET), Vuelta de Obligado 2490, Ciudad Teixeira, F.C.O.B.; Greve, B.; Autónoma de Buenos Aires (C1428ADN), Buenos Aires 2700, Argentina; [email protected] Espinoza-Sánchez, N.A.; Cristina, C.; 6 Department of Radiotherapy—Radiooncology, Münster University Hospital, Robert-Koch-Str.
    [Show full text]